No Data
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus' Board of Directors granted
B.Riley Financial Maintains Agenus(AGEN.US) With Buy Rating, Maintains Target Price $42
B.Riley Financial analyst Mayank Mamtani maintains $Agenus(AGEN.US)$ with a buy rating, and maintains the target price at $42.According to TipRanks data, the analyst has a success rate of 26.2% and a
Buy Rating Affirmed for Agenus Amid Promising Colorectal Cancer Study Results
H.C. Wainwright Maintains Agenus(AGEN.US) With Buy Rating, Maintains Target Price $40
H.C. Wainwright analyst Emily Bodnar maintains $Agenus(AGEN.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success rate of 38.3% and a tota
Analysts Offer Insights on Healthcare Companies: Agenus (AGEN), Merus (MRUS) and Iovance Biotherapeutics (IOVA)
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, and Robin Taylor, Chief Commercial